Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a …
DVT Catenacci, NC Tebbutt, I Davidenko… - The lancet …, 2017 - thelancet.com
Background Rilotumumab is a fully human monoclonal antibody that selectively targets the
ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy …
ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy …
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in …
D Cunningham, NC Tebbutt, I Davidenko, AM Murad… - 2015 - ascopubs.org
4000 Background: R is a fully human monoclonal antibody to hepatocyte growth factor. A
phase 2 study showed improved overall survival (OS) and progression-free survival (PFS) …
phase 2 study showed improved overall survival (OS) and progression-free survival (PFS) …
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label …
T Iveson, RC Donehower, I Davidenko… - The lancet …, 2014 - thelancet.com
Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes
tumour growth and metastasis. Rilotumumab is a fully human, monoclonal antibody that …
tumour growth and metastasis. Rilotumumab is a fully human, monoclonal antibody that …
[HTML][HTML] Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro …
YJ Bang, EY Ruiz, E Van Cutsem, KW Lee, L Wyrwicz… - Annals of …, 2018 - Elsevier
Background There currently are no internationally recognised treatment guidelines for
patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in …
patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in …
Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine …
KS Oliner, R Tang, A Anderson, Y Lan, T Iveson… - 2012 - ascopubs.org
4005 Background: R is an investigational, fully human, monoclonal antibody to HGF/SF, the
ligand of the MET receptor. A double-blind, P-controlled, phase 2 study randomized 121 …
ligand of the MET receptor. A double-blind, P-controlled, phase 2 study randomized 121 …
Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced …
MH Moehler, M Dvorkin, M Ozguroglu, M Ryu… - 2020 - ascopubs.org
278 Background: We report the primary analysis of JAVELIN Gastric 100, which compared
avelumab (anti–PD-L1) maintenance after 1L CTx vs continued CTx in patients (pts) with …
avelumab (anti–PD-L1) maintenance after 1L CTx vs continued CTx in patients (pts) with …
Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b …
HC Chung, HT Arkenau, J Lee, SY Rha, DY Oh… - … for immunotherapy of …, 2019 - Springer
Background We evaluated the antitumor activity and safety of avelumab, a human anti–PD-
L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in …
L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in …
[HTML][HTML] Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or …
N Boku, MH Ryu, K Kato, HC Chung, K Minashi… - Annals of …, 2019 - Elsevier
Background Nivolumab is approved as an option for third-or later-line treatment of advanced
gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2 …
gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2 …
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
SQ Yuan, RC Nie, Y Jin, CC Liang, YF Li, R Jian… - Nature Medicine, 2024 - nature.com
Perioperative chemotherapy is the standard treatment for locally advanced gastric or gastro-
esophageal junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …
esophageal junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …
Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer
YJ Bang, JY Cho, YH Kim, JW Kim… - Clinical Cancer …, 2017 - AACR
Purpose: Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte–associated
protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase …
protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase …